Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 ...

Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

About Kailera Therapeutics Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and ...

A mum has accidentally become TikTok famous after sharing her Mounjaro experience. Sharon McCandless went viral overnight for posting her personal diary online after starting weight loss medication.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

When I began Ozempic, in April 2023, I was in the doldrums of perimenopause, with high cholesterol, prediabetic blood sugar ...

The labels for diabetes therapies Ozempic and Trulicity ... caused by Ozempic and Mounjaro (tirzepatide), Lilly’s dual GLP-1/GIP agonist. An unexpected side effect has led Keros to halt dosing ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...